MENU
CANC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Oct 02, 2026

CANC in downward trend: price dove below 50-day moving average on September 23, 2026

CANC moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In 43 of 53 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In 22 of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

The 10-day moving average for CANC crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for CANC entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in 171 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF (CANC) ETF is 65.49B. The market cap for tickers in the group ranges from 2.46B to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is IMNM at 2.46B.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF (CANC) ETF was -1%. For the same ETF, the average monthly price growth was -7%, and the average quarterly price growth was 10%. IOVA experienced the highest price growth at 29%, while CELC experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF (CANC) ETF was 14%. For the same stocks of the ETF, the average monthly volume growth was 13% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 64
Price Growth Rating: 47
SMR Rating: 80
Profit Risk Rating: 75
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co
CANC in downward trend: price dove below 50-day moving average on September 23, 2026